What is a typical DSIP dosage?

There is no established typical DSIP dosage. Small human sleep studies often used 25 nmol/kg, about 21.3 micrograms/kg, by monitored intravenous infusion. That figure has not been validated as a subcutaneous regimen or an at-home schedule. A prescriber must work from the specific formulation, route, patient history and pharmacy label.

What DSIP dose did human sleep studies use?

Several small studies used 25 nmol/kg intravenously. One involved 6 people with chronic insomnia, another involved 6 healthy volunteers, and a later trial involved 16 people with chronic insomnia. These studies used different timing and reported inconsistent outcomes, so their shared dose is a historical research detail rather than a clinical standard.

When was DSIP given relative to bedtime in studies?

The timing varied substantially. Published experiments administered DSIP immediately before bedtime, about one hour before bedtime, in late afternoon, or even in the morning. Reported changes did not consistently begin right after infusion. This variability is one reason the literature does not establish a preferred interval relative to sleep onset.

How long is the DSIP half-life?

FDA's 2026 scientific review described an approximately 8-minute plasma half-life, but also found limited pharmacokinetic information and no data for the nominated subcutaneous route. Rapid disappearance from blood does not define the duration of a sleep-related effect or a dosing interval, because downstream effects may follow a different time course.

What did the July 2026 FDA committee recommendation mean for DSIP?

It was a nonbinding recommendation against adding emideltide free base and acetate to the 503A bulk drug substances list. It was not final rulemaking and did not itself change federal requirements. As of August 2026, rulemaking remained pending, and an individual prescribing decision remained with a licensed provider and patient.

DSIP Dosage: What the Human Studies Used

DSIP dosage does not have an established clinical standard. The small human sleep studies generally used intravenous doses around 25 nanomoles per kilogram under laboratory observation. Those experiments do not establish a subcutaneous dose, a nightly schedule, or a number that can be transferred to a compounded vial. The prescriber and pharmacy label define an individual prescription.

Delta sleep-inducing peptide is also called emideltide. For its origin, proposed biology and broader evidence, see what DSIP is and what researchers know. Here, the narrower question is what was actually administered in people—and how little that tells us about dosing today.

What published DSIP dosage studies used

The recurring figure in the human sleep literature is 25 nmol/kg, equivalent to about 21.3 micrograms per kilogram. It came from small intravenous experiments, not a modern dose-ranging program.

Study	Participants and administration	What the study found	Why it does not establish a dose
Schneider-Helmert and Schoenenberger, 1981	6 people with chronic insomnia; 25 nmol/kg by IV infusion over 4 minutes immediately before bedtime	Sleep-promoting changes appeared mainly in the second hour, with fewer interruptions reported	Six participants, one IV dose level and possible carryover between study nights
Schneider-Helmert et al., 1981	6 healthy volunteers; 25 nmol/kg by IV infusion in the morning	Median sleep time during a 130-minute observation period increased 59% versus placebo; delayed nighttime changes were also reported	Healthy volunteers, daytime administration and a very small sample
Bes et al., 1992	16 people with chronic insomnia; 25 nmol/kg by IV infusion between 5 and 7 p.m. on three treatment days	Sleep latency was numerically shorter, but most objective and subjective measures did not differ from placebo	The authors judged the effects weak and unlikely to offer major therapeutic benefit

The first insomnia experiment is reported in Experientia in 1981. The daytime pilot appears in the International Journal of Clinical Pharmacology, Therapy, and Toxicology. The later 16-person double-blind study in Neuropsychobiology in 1992 is especially important because its cautious result cuts against a simple success narrative.

These are study descriptions, not instructions. Intravenous infusion rate, medical observation and the tested formulation all mattered. None of the three studies validates converting 25 nmol/kg into a volume drawn from a subcutaneous compounded product.

Why one old trial number is not a standard dose

A standard dose normally rests on replicated trials that compare multiple dose levels, define the route, track adverse events and show a consistent relationship between exposure and outcome. DSIP does not have that evidence base.

Four gaps matter most:

Route: the sleep studies above used IV infusions. FDA's 2026 review found no pharmacokinetic or clinical evidence for the nominated subcutaneous route.
Scale: prominent controlled studies enrolled 6 or 16 people, far too few to define uncommon risks or a broadly applicable regimen.
Consistency: timing ranged from morning to immediately before bedtime, while sleep results ranged from reported improvement to weak differences from placebo.
Formulation: a nanomole-per-kilogram research dose is not the same thing as syringe volume. Concentration and pharmacy instructions determine what a volume represents.

That is why a DSIP dose copied from a forum can look precise while resting on the wrong route, concentration and evidence.

Timing relative to sleep onset is still unresolved

Timing gets attention because the early findings did not follow a simple sedative pattern. In the six-person 1981 insomnia study, the peptide was infused immediately before bedtime, yet a slight arousing effect appeared in the first hour and the reported sleep-promoting effect appeared in the second. Another small series used an infusion one hour before bedtime. The 1992 trial administered it in late afternoon. The healthy-volunteer pilot administered it in the morning and still reported delayed changes that night.

Taken together, those schedules do not identify a best interval before sleep. They show that the investigators were testing whether DSIP might alter sleep regulation beyond the moment it remained measurable in blood. A prescriber considering timing has to account for that uncertainty rather than treating one study clock time as settled practice.

The short plasma half-life does not settle the schedule

FDA's July 2026 scientific review described an approximately 8-minute plasma half-life, while also noting that pharmacokinetic information was limited and absent for subcutaneous administration. Laboratory work published in Peptides in 1987 found rapid degradation in human serum and attributed the disappearance of DSIP mainly to enzymatic breakdown. Nonhuman measurements in that literature were also on the order of minutes.

A short plasma half-life answers how quickly measurable peptide disappears from blood under particular conditions. It does not prove when a sleep-related effect begins, how long a downstream signal lasts or what dosing interval is appropriate. The human studies reported changes hours after administration, but those findings were small and inconsistent. Pharmacokinetics and clinical effect cannot be treated as the same clock.

What safety evidence can and cannot say

The FDA's 2026 emideltide briefing identified human studies in which 25 to 150 nmol/kg was given intravenously to 209 participants for periods ranging from 1 to 15 days. That is not a long-term safety program. The insomnia studies did not report significant adverse effects, while studies in people undergoing alcohol or opioid withdrawal reported transient headache, nausea, vertigo and some hypotension; the underlying withdrawal made attribution difficult.

The same review found no clinical safety data for subcutaneous emideltide and raised unresolved questions about characterization, impurities, aggregation and immune response. Absence of a reported problem in a small, short IV experiment is not evidence that a different formulation and route have been fully characterized.

What the July 2026 FDA recommendation means

At its July 24, 2026 meeting, the Pharmacy Compounding Advisory Committee did not recommend emideltide free base or emideltide acetate for inclusion on the federal 503A bulk drug substances list. The FDA meeting record identifies chronic insomnia, narcolepsy and opioid withdrawal as the uses reviewed and explains that advisory-committee recommendations are nonbinding.

That vote was advice to FDA, not completed rulemaking, and it did not change federal requirements on its own. Rulemaking remains pending as of August 2026. A licensed provider may still prescribe a compounded formulation, and that decision remains between the patient and the doctor.

Promise's DSIP is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. This regulatory distinction is separate from the clinical question of whether a prescription makes sense for one person.

How a prescriber approaches DSIP dosing

Because there is no standard DSIP dose, the decision begins with the reason for the request and the quality of the evidence behind it. The clinician also weighs sleep history, other conditions, current medications, prior reactions, formulation concentration, route and the partner pharmacy's labeling. Persistent insomnia can have causes that call for a different evaluation entirely.

At Promise, a licensed provider reviews every request and may prescribe DSIP only when it is medically appropriate; not everyone qualifies. People comparing peptide options by goal can also browse calming and stress-support care, while the prescription process for peptides explains what happens between intake and pharmacy dispensing.

A responsible DSIP dosing discussion ends with the evidence gap in view: 25 nmol/kg describes several old IV experiments, not a universal prescription. Route, concentration, timing and monitoring remain clinical decisions, and the available human literature is too thin to turn them into a standard schedule.